The DOI matches its Crossref record; 72 of the 74 references it cites were found in a registry or an index.
ApoE Promotes the Proteolytic Degradation of Aβ
Open accessAbstract
Apolipoprotein E is associated with age-related risk for Alzheimer's disease and plays critical roles in Abeta homeostasis. We report that ApoE plays a role in facilitating the proteolytic clearance of soluble Abeta from the brain. The endolytic degradation of Abeta peptides within microglia by neprilysin and related enzymes is dramatically enhanced by ApoE. Similarly, Abeta degradation extracellularly by insulin-degrading enzyme is facilitated by ApoE. The capacity of ApoE to promote Abeta degradation is dependent upon the ApoE isoform and its lipidation status. The enhanced expression of lipidated ApoE, through the activation of liver X receptors, stimulates Abeta degradation. Indeed, aged Tg2576 mice treated with the LXR agonist GW3965 exhibited a dramatic reduction in brain Abeta load. GW3965 treatment also reversed contextual memory deficits. These data demonstrate a mechanism through which ApoE facilitates the clearance of Abeta from the brain and suggest that LXR agonists may represent a novel therapy for AD.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“APOE3 promotes enzyme-mediated degradation of A 𝛃 in microglia more efficiently than APOE4 (295), suggesting the APOE and microglia play a role in the innate immune response in AD (368).”
From Blood-Brain Barrier: From Physiology to Disease and Back (2019) · cites this paper as [295]
In the citing paper
“In this regard, ApoE is indeed tightly connected to the turnover of Ab 1 -42 , since it plays a critical role in the normal proteolytic clearance of Ab 1 -42 (14).”
From SUCLG2 identified as both a determinator of CSF Aβ1–42 levels and an attenuator of cognitive decline in Alzheimer's disease (2014) · cites this paper as [14]
In the citing paper
“One recent in vitro study found that human apoE isoforms differed in their ability to facilitate neprilysin-mediated degradation of Aβ42 within microglia, with apoE4 being the least effective in facilitating Aβ degradation compared to apoE2 or apoE3 (60).”
From Human ApoE isoforms differentially regulate brain amyloid-β peptide clearance (2011) · cites this paper as [60]
In the citing paper
“Several studies demonstrated that apoE isoforms can differentially affect Aβ clearance (Deane et al., 2008; Jiang et al., 2008; Castellano et al., 2011).”
From Haploinsufficiency of Human APOE Reduces Amyloid Deposition in a Mouse Model of Amyloid-β Amyloidosis (2011) · cites this paper as Jiang et al., 2008
In the citing paper
“In addition, several studies have shown that activation of Lxr increases mouse apoE and decreases Aβ levels (Jiang et al., 2008).”
From Haploinsufficiency of Human APOE Reduces Amyloid Deposition in a Mouse Model of Amyloid-β Amyloidosis (2011) · cites this paper as Jiang et al., 2008
In the citing paper
“LXR agonist treatment alleviates AD-like pathology in mouse models of amyloidosis, possibly by inducing Abca1 expression (29, 43–48).”
From The E3 ubiquitin ligase Idol controls brain LDL receptor expression, ApoE clearance, and Aβ amyloidosis (2015) · cites this paper as [29]
In the citing paper
“In addition to its role in A secretion, ABCA1 has been also shown to decrease A levels by promoting extracellular A clearance in both neurons and glial cells (Jiang et al., 2008;Kim et al., 2012).”
From microRNA-33 Regulates ApoE Lipidation and Amyloid-β Metabolism in the Brain (2015) · cites this paper as Jiang et al., 2008
In the citing paper
“A previous report demonstrated that extracellular A degradation by proteases, such as insulin-degrading enzyme, is influenced by the lipidation status of ApoE (Jiang et al., 2008).”
From microRNA-33 Regulates ApoE Lipidation and Amyloid-β Metabolism in the Brain (2015) · cites this paper as Jiang et al., 2008
In the citing paper
“ApoE lipidation by ABCA1 is critical for A clearance (Jiang et al., 2008;Kim et al., 2012).”
From microRNA-33 Regulates ApoE Lipidation and Amyloid-β Metabolism in the Brain (2015) · cites this paper as Jiang et al., 2008
In the citing paper
“we and others have shown that ABCA1 is required for the effective clearance of A by neuronal and glial cells”
From microRNA-33 Regulates ApoE Lipidation and Amyloid-β Metabolism in the Brain (2015) · cites this paper as Jiang et al., 2008
In the citing paper
“A recent in vitro study demonstrated that the presence of fully lipidated apoE is required for effective degradation of Aβ in microglia (Jiang et al., 2008; Terwel et al., 2011).”
From miR-106b impairs cholesterol efflux and increases Aβ levels by repressing ABCA1 expression (2012) · cites this paper as Jiang et al., 2008
In the citing paper
“More recent studies in transgenic mouse models of AD have shown that microglia migrate to amyloid plaques and may alter plaque growth dynamics (9–12).”
From Attenuating astrocyte activation accelerates plaque pathogenesis in APP/PS1 mice (2013) · cites this paper as [10]
In the citing paper
“ABCA1-mediated lipidation of apoE may play a key role in facilitating Aβ degradation by Aβ-degrading enzymes (Jiang et al., 2008).”
From Apolipoprotein E in Synaptic Plasticity and Alzheimer’s Disease: Potential Cellular and Molecular Mechanisms (2014) · cites this paper as Jiang et al., 2008
In the citing paper
“In addition, treatment of several AD Tg mice models with liver X receptor or retinoid X receptor agonists, which upregulate ApoE expression and enhance its lipidation status, resulted in reduction of Ab plaque load through enhancing clearance of Ab by glial cells.43,44”
From Blocking the Interaction between Apolipoprotein E and Aβ Reduces Intraneuronal Accumulation of Aβ and Inhibits Synaptic Degeneration (2013) · cites this paper as [43]
In the citing paper
“These published data indicate that the ApoE/Ab interaction may result in multidirectional effects that may promote Ab degradation by nonneuronal cells 43,44 while enhancing Ab accumulation in neurons.”
From Blocking the Interaction between Apolipoprotein E and Aβ Reduces Intraneuronal Accumulation of Aβ and Inhibits Synaptic Degeneration (2013) · cites this paper as [43]
In the citing paper
“Short-term administration of LXR agonists TO901317 and GW3965 to 5-month-old preplaque Tg2576 mice improved fear conditioning (Riddell et al., 2007;Jiang et al., 2008)”
From Critical Role of Astroglial Apolipoprotein E and Liver X Receptor-α Expression for Microglial Aβ Phagocytosis (2011) · cites this paper as Jiang et al., 2008
In the citing paper
“Long-term treatment with GW3965 has been shown to reduce plaque formation by 50% in aged Tg2576 mice (Jiang et al., 2008).”
From Critical Role of Astroglial Apolipoprotein E and Liver X Receptor-α Expression for Microglial Aβ Phagocytosis (2011) · cites this paper as Jiang et al., 2008
In the citing paper
“Previously, it has been observed that the LXR agonist GW3965 stimulates degradation of soluble A in astroglial and microglial cultures dependent on ApoE and its lipidation status (Jiang et al., 2008).”
From Critical Role of Astroglial Apolipoprotein E and Liver X Receptor-α Expression for Microglial Aβ Phagocytosis (2011) · cites this paper as Jiang et al., 2008
In the citing paper
“Importantly, apoE-containing HDL particles facilitate the proteolytic degradation of soluble Aβ (sAβ) (Jiang et al., 2008).”
From Mechanisms Underlying the Rapid Peroxisome Proliferator-Activated Receptor-γ-Mediated Amyloid Clearance and Reversal of Cognitive Deficits in a Murine Model of Alzheimer's Disease (2012) · cites this paper as Jiang et al., 2008
In the citing paper
“We report that astrocytes have the capacity to take up sAβ and degrade it in an apoE-dependent manner, similar to microglia (Figs. 1, 2; Jiang et al., 2008).”
From Mechanisms Underlying the Rapid Peroxisome Proliferator-Activated Receptor-γ-Mediated Amyloid Clearance and Reversal of Cognitive Deficits in a Murine Model of Alzheimer's Disease (2012) · cites this paper as Jiang et al., 2008
In the citing paper
“We have previously documented that apoE acts to facilitate the proteolysis of soluble Aβ peptides both in the interstitial fluid and intracellularly by microglia through the actions of IDE and neprilysin, respectively (Jiang et al., 2008).”
From Mechanisms Underlying the Rapid Peroxisome Proliferator-Activated Receptor-γ-Mediated Amyloid Clearance and Reversal of Cognitive Deficits in a Murine Model of Alzheimer's Disease (2012) · cites this paper as Jiang et al., 2008
In the citing paper
“Lipidated ApoE has anti-inflammatory effects and promotes Aβ metabolism (12)”
From Nuclear SphK2/S1P signaling is a key regulator of ApoE production and Aβ uptake in astrocytes (2024) · cites this paper as [12]
In the citing paper
“the administration of RXR or LXR agonists reduces Aβ aggregation and restores cognitive function in AD mouse model (11, 12)”
From Nuclear SphK2/S1P signaling is a key regulator of ApoE production and Aβ uptake in astrocytes (2024) · cites this paper as [12]
In the citing paper
“Lipidated ApoE has anti-inflammatory effects and promotes Aβ metabolism (12)”
From Nuclear SphK2/S1P signaling is a key regulator of ApoE production and Aβ uptake in astrocytes (2024) · cites this paper as [12]
In the citing paper
“Two in vitro studies have also demonstrated that apoE can facilitate the cellular degradation of Aβ (Jiang et al., 2008; Koistinaho et al., 2004).”
From The role of apolipoprotein E in Alzheimer's disease (2009) · cites this paper as Jiang et al., 2008
In the citing paper
“suggesting that ABCA1 affects Aβ clearance via apoE (Jiang et al., 2008).”
From The role of apolipoprotein E in Alzheimer's disease (2009) · cites this paper as Jiang et al., 2008
In the citing paper
“A recent in vitro study demonstrated that the presence of fully lipidated apoE was necessary for effective degradation of Aβ in microglia, suggesting that ABCA1 affects Aβ clearance via apoE (Jiang et al., 2008).”
From The role of apolipoprotein E in Alzheimer's disease (2009) · cites this paper as Jiang et al., 2008
In the citing paper
“One common hypothesis states that APOE sequesters soluble Aβ in the extracellular space resulting in cellular uptake and catabolism of this neurotoxic peptide. This hypothesis is supported by many in vitro studies (Koistinaho et al., 2004; Morikawa et al., 2005; Jiang et al., 2008).”
From The Pro-Neurotrophin Receptor Sortilin Is a Major Neuronal Apolipoprotein E Receptor for Catabolism of Amyloid-β Peptide in the Brain (2013) · cites this paper as Jiang et al., 2008
In the citing paper
“In the brain, endocytic pathways in glia cells (likely the LDL receptor) and in neurons are implicated in cellular catabolism of APOE/Aβ complexes (Koistinaho et al., 2004; Jiang et al., 2008; Holtzman et al., 2012).”
From The Pro-Neurotrophin Receptor Sortilin Is a Major Neuronal Apolipoprotein E Receptor for Catabolism of Amyloid-β Peptide in the Brain (2013) · cites this paper as Jiang et al., 2008
In the citing paper
“ApoE4 cells are less efficient in promoting intracellular A42 degradation compared with ApoE3 cells (Jiang et al., 2008).”
From ApoE4 Alters ABCA1 Membrane Trafficking in Astrocytes (2019) · cites this paper as Jiang et al., 2008
Citations
Cites
The Amyloid Hypothesis of Alzheimer’s Disease: Progress and Problems on the Road to Therapeutics
Hardy, J., & Selkoe, D. J. (2002) · Science · doi:10.1126/science.1072994 · Cited by 13,864
Amyloid oligomers exacerbate tau pathology in a mouse model of tauopathy
Selenica, M.-L. B., Brownlow, M., Jimenez, J. P., Lee, D. C., Pena, G., Dickey, C. A., Gordon, M. N., & Morgan, D. (2013) · Neurodegenerative Diseases · doi:10.1159/000337230 · Cited by 10,359
Twenty years of the Alzheimer's disease amyloid hypothesis: a genetic perspective
Tanzi, R. E., & Bertram, L. (2005) · Cell · doi:10.1016/j.cell.2005.02.008 · Cited by 1,849
Farris, W., Mansourian, S., Chang, Y., Lindsley, L., Eckman, E. A., Frosch, M. P., Eckman, C. B., Tanzi, R. E., Selkoe, D. J., & Guénette, S. Y. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0230450100 · Cited by 1,526
Deciphering the Molecular Basis of Memory Failure in Alzheimer's Disease
Walsh, D. M., & Selkoe, D. J. (2004) · Neuron · doi:10.1016/j.neuron.2004.09.010 · Cited by 1,207
Kawarabayashi, T., Younkin, L. H., Saido, T. C., Shoji, M., Ashe, K. H., & Younkin, S. G. (2001) · The Journal of Neuroscience · doi:10.1523/jneurosci.21-02-00372.2001 · Cited by 1,053 · cited 2×
“, 1995) and exhibit extensive deposits of Aβ by one year of age (Kawarabayashi et al., 2001).”
BackgroundMetabolic Regulation of Brain Aβ by Neprilysin
Iwata, N., Tsubuki, S., Takaki, Y., Shirotani, K., Lu, B., Gerard, N. P., Gerard, C. J., Hama, E., Lee, H.-J., & Saido, T. C. (2001) · Science · doi:10.1126/science.1059946 · Cited by 982
Liver X receptors as integrators of metabolic and inflammatory signaling
Zelcer, N. (2006) · Journal of Clinical Investigation · doi:10.1172/jci27883 · Cited by 978
Self-citationIwata, N., Tsubuki, S., Takaki, Y., Watanabe, K., Sekiguchi, M., Hosoki, E., Kawashima-Morishima, M., Lee, H.-J., Hama, E., Sekine-Aizawa, Y., et al. (2000) · Nature Medicine · doi:10.1038/72237 · Cited by 867
Lack of apolipoprotein E dramatically reduces amyloid β-peptide deposition
Bales, K. R., Verina, T., Dodel, R. C., Du, Y., Altstiel, L., Bender, M., Hyslop, P., Johnstone, E. M., Little, S. P., Cummins, D. J., et al. (1997) · Nature Genetics · doi:10.1038/ng1197-263 · Cited by 830
Flagged first, then by citations
2 of the 74 references couldn’t be matched to a known paper.
Cited by
Sorted by citations
Items 601–700 of 875
Rogers, D. A., & Schor, N. F. (2009) · Annals of Neurology · doi:10.1002/ana.21841 · Cited by 15
Martens, N., Zhan, N., Yam, S. C., Leijten, F. P. J., Palumbo, M., Caspers, M. P. M., Tiane, A., Friedrichs, S., Li, Y., der Zee, L. V. V., et al. (2024) · Nutrients · doi:10.3390/nu16111614 · Cited by 15
Nuclear SphK2/S1P signaling is a key regulator of ApoE production and Aβ uptake in astrocytes
Komai, M., Noda, Y., Ikeda, A., Kaneshiro, N., Kamikubo, Y., Sakurai, T., Uehara, T., & Takasugi, N. (2024) · Journal of Lipid Research · doi:10.1016/j.jlr.2024.100510 · Cited by 13
Park, K. H. J., & Barrett, T. (2020) · Journal of Alzheimer s Disease Reports · doi:10.3233/adr-200170 · Cited by 12
Scarfò, G., Piccarducci, R., Daniele, S., Franzoni, F., & Martini, C. (2022) · Antioxidants · doi:10.3390/antiox11112116 · Cited by 16
Redox status of serum apolipoprotein E and its impact on HDL cholesterol levels
Yamauchi, K., Ebihara, Y., & Kawakami, Y. (2017) · Clinical Biochemistry · doi:10.1016/j.clinbiochem.2017.03.021 · Cited by 13
Nuclear receptors of NR1 and NR4 subfamilies in the regulation of microglial functions and pathology
Katsuki, H. (2021) · Pharmacology Research & Perspectives · doi:10.1002/prp2.766 · Cited by 14
Huang, P.-Y. S., Hsieh, S., Chang, Y., Hour, A., Chen, H., & Liu, C. (2017) · Geriatrics and gerontology international/Geriatrics & gerontology international · doi:10.1111/ggi.13059 · Cited by 14
Cathepsin D: A Candidate Link between Amyloid ?-protein and Tauopathy in Alzheimer Disease
Suire, C. N., & Leissring, M. A. (2021) · Journal of Experimental Neurology · doi:10.33696/neurol.2.029 · Cited by 15
Putative pathological mechanisms of late-life depression and Alzheimer’s disease
Hasan, S. M. N., Clarke, C., Strand, T., & Bambico, F. R. (2023) · Brain Research · doi:10.1016/j.brainres.2023.148423 · Cited by 13
Machine Learning–Based Perivascular Space Volumetry in Alzheimer Disease
Deike‐Hofmann, K., Decker, A., Scheyhing, P., Harten, J., Zimmermann, N., Paech, D., Peters, O., Freiesleben, S. D., Schneider, L., Preis, L., et al. (2024) · Investigative Radiology · doi:10.1097/rli.0000000000001077 · Cited by 12
Moosecker, S., Pissioti, A., Leidmaa, E., Harb, M. R., Dioli, C., Gassen, N. C., Yu, S., Gazea, M., Catania, C., Anderzhanova, E., et al. (2021) · Neuroscience · doi:10.1016/j.neuroscience.2021.10.029 · Cited by 12
[Genetic polymorphism of apolipoprotein E in a Peruvian population].
Marca, V., Acosta, Ó., Cornejo‐Olivas, M., Ortega, O., Huerta, D., & Mazzetti, P. (2011) · PubMed · Cited by 12
Blood–Brain Barrier Transport of Alzheimer’s Amyloid β-Peptide
Nelson, A. R., Sagare, A. P., & Zloković, B. V. (2016) · Elsevier eBooks · doi:10.1016/b978-0-12-802173-6.00009-5 · Cited by 12
Viktorsson, E. Ö., Gabrielsen, M., Kumarachandran, N., Sylte, I., Rongved, P., Åstrand, O. A. H., & Kase, E. T. (2016) · Steroids · doi:10.1016/j.steroids.2016.12.003 · Cited by 14
Neuroinflammation drives APOE genotype-dependent differential expression of neprilysin
Graykowski, D. R., Kasparian, K., Caniglia, J. L., Gritsaeva, Y., & Cudaback, E. (2020) · Journal of Neuroimmunology · doi:10.1016/j.jneuroim.2020.577315 · Cited by 12
Effects of Alzheimer’s Disease-Related Proteins on the Chirality of Brain Endothelial Cells
Zhang, H., Fan, J., Zhao, Z., Wang, C., & Wan, L. Q. (2021) · Cellular and Molecular Bioengineering · doi:10.1007/s12195-021-00669-w · Cited by 11
ApoE: The link between Alzheimer’s-related glucose hypometabolism and Aβ deposition?
Patil, S. P., Ballard, R., Sanchez, S., Osborn, J., & Santangelo, D. (2012) · Medical Hypotheses · doi:10.1016/j.mehy.2012.01.015 · Cited by 13
Lukkahatai, N., Patel, S., Guček, M., Hsiao, C., & Saligan, L. N. (2013) · Journal of Pain and Symptom Management · doi:10.1016/j.jpainsymman.2013.05.016 · Cited by 12
Commentary on Some Recent Theses Relevant to Combating Aging: August 2013
Zealley, B., & de Grey, A. D. N. J. (2013) · Rejuvenation Research · doi:10.1089/rej.2013.1464 · Cited by 12
Giorgio, J., Jonson, C., Wang, Y., Yokoyama, J. S., Wang, J., Jagust, W. J., & Initiative, O. B. O. T. A. D. N. (2025) · Nature Communications · doi:10.1038/s41467-025-60370-8 · Cited by 14
Effect of LXR/RXR agonism on brain and CSF Aβ40 levels in rats
Wang, S., Wen, P. H., & Wood, S. J. (2016) · F1000Research · doi:10.12688/f1000research.7868.2 · Cited by 11
Regulation of Alzheimer's disease-associated proteins during epileptogenesis
von Rüden, E., Zellinger, C., Gedon, J., Walker, A., Bierling, V., Deeg, C. A., Hauck, S. M., & Potschka, H. (2019) · Neuroscience · doi:10.1016/j.neuroscience.2019.08.037 · Cited by 11
Lipolysis-Stimulated Lipoprotein Receptor Acts as Sensor to Regulate ApoE Release in Astrocytes
Herzine, A., Sekkat, G., Kaminski, S., Calcagno, G., Boschi‐Müller, S., Safi, H., Corbier, C., Visvikis‐Siest, S., Claudepierre, T., & Yen, F. T. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23158630 · Cited by 11
APOE ε4genotype predicts memory for everyday activities
Bailey, H. R., Sargent, J. Q., Flores, S. E., Nowotny, P., Goate, A., & Zacks, J. M. (2015) · Aging Neuropsychology and Cognition · doi:10.1080/13825585.2015.1020916 · Cited by 12
Viable mouse gene ablations that robustly alter brain Aβ levels are rare
Toyn, J. H., Lin, X.-A., Thompson, M. W., Guss, V. L., Meredith, J. E., Sankaranarayanan, S., Barrezueta, N. X., Corradi, J., Majumdar, A., Small, D. L., et al. (2010) · BMC Neuroscience · doi:10.1186/1471-2202-11-143 · Cited by 11
Toedebusch, C. M., Garcia, V. B., Snyder, J. C., Jones, M. R., Schulz, D. J., Johnson, G. C., Villalón, E., Coates, J. R., & Garcia, M. L. (2019) · GeroScience · doi:10.1007/s11357-019-00133-8 · Cited by 13
Map kinase and PKC signaling pathways modulate NGF-mediated apoE transcription
Strachan-Whaley, M. R., Reilly, K., Dobson, J., & Kalisch, B. E. (2015) · Neuroscience Letters · doi:10.1016/j.neulet.2015.03.032 · Cited by 12
Washington, P. M., & Burns, M. P. (2016) · Journal of Neuropathology & Experimental Neurology · doi:10.1093/jnen/nlw049 · Cited by 11
Tice, C. M., Noto, P. B., Fan, K. Y., Zhao, W. L., Lotesta, S. D., Dong, C., Marcus, A. P., Zheng, Y., Chen, G., Wu, Z., et al. (2016) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2016.08.089 · Cited by 12
Effects of DHA (omega-3 fatty acid) and estradiol on amyloid β-peptide regulation in the brain
Majou, D., & Dermenghem, A.-L. (2023) · Brain Research · doi:10.1016/j.brainres.2023.148681 · Cited by 10
The genetic landscape of basal ganglia and implications for common brain disorders
Bahrami, S., Nordengen, K., Rokicki, J., Shadrin, A. A., Rahman, Z., Smeland, O. B., Jaholkowski, P. P., Parker, N., Parekh, P., O’Connell, K. S., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-52583-0 · Cited by 16
Casali, B. T., Lin, L. W., Benedict, O., Zuppe, H. T., Marsico, E., & Reed-Geaghan, E. G. (2025) · Journal of Neuroinflammation · doi:10.1186/s12974-025-03404-8 · Cited by 13
Targeting Glucocorticoid Receptors: A New Avenue for Alzheimer’s Disease Therapy
Canet, G., Chevallier, N., Perrier, V., Desrumaux, C. M., & Givalois, L. (2018) · Springer eBooks · doi:10.1007/978-981-13-0944-1_15 · Cited by 10
Regulation of cytochrome P450 4F11 expression by liver X receptor alpha
Zhang, T., Zhan, Z., Chen, Y., Chen, J., Han, W., Liang, Z., Liu, Q., Liu, S., & Tang, L. (2020) · International Immunopharmacology · doi:10.1016/j.intimp.2020.107240 · Cited by 11
Apolipoprotein E receptor pathways in Alzheimer disease
Schmidt, V., Carlo, A.-S., & Willnow, T. E. (2014) · WIREs Systems Biology and Medicine · doi:10.1002/wsbm.1262 · Cited by 10
Moon, S. W., Byun, M. S., Yi, D., Lee, J. H., Jeon, S. Y., Lee, Y., Kee, B. S., & Lee, D. Y. (2018) · The Journals of Gerontology Series A · doi:10.1093/gerona/gly157 · Cited by 10
Oh, J., Nam, Y., Jo, A., Cheon, H., Rhee, S., Park, J., Lee, J., & Kim, H. K. (2010) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2010.06773.x · Cited by 10
Kim, W. S., Hill, A. F., Fitzgerald, M. L., Freeman, M. W., Evin, G. M., & Garner, B. (2011) · Journal of Alzheimer s Disease · doi:10.3233/jad-2011-110521 · Cited by 10
Sidiropoulos, C., Jafari‐Khouzani, K., Hamid Soltanian-zadeh, A., Mitsias, P. D., Alexopoulos, P., Richter‐Schmidinger, T., Reichel, M., Lewczuk, P., Doerfler, A., & Kornhuber, J. (2011) · Acta Neuropsychiatrica · doi:10.1111/j.1601-5215.2011.00546.x · Cited by 11
Bojar, I., Stasiak, M., Cyniak-Magierska, A., Raczkiewicz, D., & Lewiñski, A. (2016) · Dementia and Geriatric Cognitive Disorders · doi:10.1159/000449373 · Cited by 10
Parkinson's disease: a long and difficult journey.
Casey, G. (2013) · PubMed · Cited by 10
Retinoid X receptor‐α mediates (R )‐flurbiprofen’s effect on the levels of Alzheimer’s β‐amyloid
You, X., Zhang, Y., Chen, Y., Huang, X., Xu, R., Cao, X., Chen, J., Liu, Y., Zhang, X.-K., & Xu, H. (2009) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2009.06312.x · Cited by 10
Protein Interactome of Amyloid-β as a Therapeutic Target
Lazarev, V. F., Dutysheva, E. A., Kanunikov, I. E., Guzhova, I. V., & Margulis, B. A. (2023) · Pharmaceuticals · doi:10.3390/ph16020312 · Cited by 9
Choi, Y., Shin, S., Son, H. J., Lee, N.-H., Myeong, S. H., Lee, C., Jang, H., Choi, S. J., Kim, H. J., & Na, D. L. (2023) · Stem Cell Research & Therapy · doi:10.1186/s13287-023-03410-8 · Cited by 9
Self-citationShan, X., Li, D., Yin, H., Tao, W., Zhou, L., Gao, Y. W., Xing, C., & Zhang, C. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26031207 · Cited by 8
Microglia energy metabolism: A new perspective on Alzheimer's disease treatment
Wu, Q.-L., Yang, X., Luo, J.-X., Liu, L., Zhou, Y., & Lu, M. (2025) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2025.123585 · Cited by 12
Moderating Role of Cognitive Reserve Markers Between Childhood Cognition and Cognitive Aging
Almeida‐Meza, P., Richards, M., & Cadar, D. (2022) · Neurology · doi:10.1212/wnl.0000000000200928 · Cited by 9
A case of amyloid-β-related cerebral angiitis with ApoE ε4/ε2 genotype
Ogura, A., Moriyoshi, H., Nakai, N., Nishida, S., Kitagawa, S., Yoshida, M., Yasuda, T., & Ito, Y. (2015) · Rinsho Shinkeigaku · doi:10.5692/clinicalneurol.cn-000685 · Cited by 9
Asiamah, E. A., Feng, B., Guo, R., Yaxing, X., Du, X., Liu, X., Zhang, J., Cui, H., & Ma, J. (2024) · Journal of Alzheimer s Disease · doi:10.3233/jad-230658 · Cited by 8
Amukti, D. P., Wazni, A. R., Irham, L. M., Sulistyani, N., Ma’ruf, M. F., Adikusuma, W., Sarasmita, M. A., Khairi, S., Purwanto, B. D., Suyatmi, S., et al. (2024) · E3S Web of Conferences · doi:10.1051/e3sconf/202450101021 · Cited by 8
Goel, D., Faruq, M., Nazir, S. S., Kaushik, P., Parvez, S., & Vohora, D. (2025) · Journal of Neurochemistry · doi:10.1111/jnc.70007 · Cited by 8
Peng, H., Bukuroshi, P., Durk, M. R., Grootendorst, P. V., Yan, X., Pan, S. R., de Lannoy, I. A. M., & Pang, K. S. (2021) · Biopharmaceutics & Drug Disposition · doi:10.1002/bdd.2297 · Cited by 8
Neurobiological correlation between phosphorylated tau and mood symptoms in memory clinic patients
Ozaki, T. J., Hashimoto, N., Udo, N., Narita, H., Nakagawa, S., & Kusumi, I. (2023) · Psychogeriatrics · doi:10.1111/psyg.13016 · Cited by 8
Bonnar, O., Shaw, K., Anderle, S., Grijseels, D. M., Clarke, D., Bell, L., King, S. L., & Hall, C. N. (2023) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1177/0271678x231172842 · Cited by 8
Neuropathologie morphologique et moléculaire de la maladie d’Alzheimer
Duyckaerts, C. J., Panchal, M., Delatour, B., & Potier, M. (2009) · Annales Pharmaceutiques Françaises · doi:10.1016/j.pharma.2009.01.001 · Cited by 11
Lipid metabolism and Alzheimer's disease: pathways and possibilities
Saxena, U. (2009) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728220902738720 · Cited by 9
Mallick, S., Marshall, P. A., Wagner, C. E., Heck, M. C., Sabir, Z. L., Sabir, M. S., Dussik, C. M., Grozić, A., Kaneko, I., & Jurutka, P. W. (2021) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.0c00707 · Cited by 8
Rao, A. T., Chen, N., Kim, M. J., Blumenfeld, J. R., Yip, O., Hao, Y., Liang, Z., Nelson, M. R., Koutsodendris, N., Grone, B. P., et al. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.11.10.566510 · Cited by 8
How Do Retinoids Affect Alzheimer’s Disease and Can They Be Novel Drug Candidates?
Alsharief, M. (2024) · Cureus · doi:10.7759/cureus.57548 · Cited by 8
Grenon, M. B., Papavergi, M.-T., Bathini, P., Sadowski, M. J., & Lemere, C. A. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25115754 · Cited by 7
Martens, N., Zhan, N., Yam, S. C., Palumbo, M., Pontini, L., Leijten, F. P. J., der Zee, L. V. V., Voortman, G. J., Friedrichs, S., Gerding, A., et al. (2025) · British Journal of Pharmacology · doi:10.1111/bph.70031 · Cited by 7
Twitto‐Greenberg, R., Zaltsman, S. L., Michaelson, D. M., Liraz, O., Lubitz, I., Atrakchi, D., Shemesh, C., Ashery, U., Cooper, I., Harari, A., et al. (2023) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2023.09.005 · Cited by 7
Astrocyte–Neuron Interactions in Alzheimer’s Disease
Muñoz‐Castro, C., & Serrano‐Pozo, A. (2024) · Advances in neurobiology · doi:10.1007/978-3-031-64839-7_14 · Cited by 7
Strategizing the Development of Alzheimer’s Therapeutics
Davis, J. B., & Couch, R. D. (2014) · Advances in Alzheimer s Disease · doi:10.4236/aad.2014.33011 · Cited by 7
New APOE-related therapeutic options for Alzheimer’s disease
Li, Z. (2019) · AIP conference proceedings · doi:10.1063/1.5085515 · Cited by 8
Allopregnanolone as a Therapeutic to Regenerate the Degenerated Brain
Hernandez, G. D., & Brinton, R. D. (2019) · ISGE series · doi:10.1007/978-3-030-11355-1_7 · Cited by 7
Type II nuclear receptors with potential role in Alzheimer disease
Muñoz-Cabrera, J., Adrián, S.-H., & Arboleda, G. (2021) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2020.100940 · Cited by 9
Kota, L. N., Bharath, S., Purushottam, M., Paul, P., Sivakumar, P. T., Varghese, M., & Jain, S. (2014) · Asian Journal of Psychiatry · doi:10.1016/j.ajp.2014.06.012 · Cited by 7
Aβ regulation-based multitarget strategy for drug discovery against Alzheimer’s disease
Guo, X., Jiang, W., Li, C., Zhu, Z., & Shen, X. (2014) · Reviews in the Neurosciences · doi:10.1515/revneuro-2014-0064 · Cited by 7
Sandoval-Hernández, A. G., Contreras-Zarate, M. J., Jaramillo, J., & Arboleda, G. (2016) · Advances in experimental medicine and biology · doi:10.1007/978-3-319-40764-7_14 · Cited by 7
Stachowicz, A., Olszanecki, R., Suski, M., Głombik, K., Basta‐Kaim, A., Adamek, D., & Korbut, R. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18020435 · Cited by 8
Sarlak, Z., Moazzami, M., Hosseini, S. R. A., & Gharakhanlou, R. (2019) · PubMed · doi:10.22038/ijbms.2018.32911.7860 · Cited by 7
Modulation of Actin network and Tau phosphorylation by HDAC6 ZnF UBP domainPreprint
Balmik, A. A., Sonawane, S. K., & Chinnathambi, S. (2019) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/702571 · Cited by 7
Kanuri, S. H., & Sirrkay, P. J. (2025) · Neurology International · doi:10.3390/neurolint17090134 · Cited by 7
ApoE Isoforms Inhibit Amyloid Aggregation of Proinflammatory Protein S100A9
Ghosh, S., Tamilselvi, S., Williams, C., Jayaweera, S. W., Iashchishyn, I. A., Šulskis, D., Gilthorpe, J. D., Olofsson, A., Smirnovas, V., Svedružić, Ž. M., et al. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25042114 · Cited by 6
HDL-replacement therapy: From traditional to emerging clinical applications
Sirtori, C. R., Cincotto, G., Castiglione, S., & Pavanello, C. (2025) · Atherosclerosis Plus · doi:10.1016/j.athplu.2025.02.001 · Cited by 6
SHARMA, A. K., Mannan, A., & Singh, T. G. (2025) · Metabolic Brain Disease · doi:10.1007/s11011-025-01642-6 · Cited by 7
Missense substitutions associated with behavioural disturbances in Alzheimer's disease (AD)
Proitsi, P., & Powell, J. F. (2012) · Brain Research Bulletin · doi:10.1016/j.brainresbull.2012.02.010 · Cited by 6
Kikis, E. A. (2017) · Healthcare · doi:10.3390/healthcare5030046 · Cited by 6
Advances in the Study of APOE and Innate Immunity in Alzheimer’s Disease
Li, Y., Chang, J., Chen, X., Liu, J., & Zhao, L. (2023) · Journal of Alzheimer s Disease · doi:10.3233/jad-230179 · Cited by 6
SCRN: Single-Cell Gene Regulatory Network Identification in Alzheimer's Disease
Zhu, W., Du, Z., Xu, Z., Yang, D., Chen, M., & Song, Q. (2024) · IEEE Transactions on Computational Biology and Bioinformatics · doi:10.1109/tcbb.2024.3424400 · Cited by 6
Coico, R., & Woodruff‐Pak, D. S. (2008) · Journal of Alzheimer s Disease · doi:10.3233/jad-2008-15411 · Cited by 6
Zhai, Y., Yamashita, T., Kurata, T., Fukui, Y., Sato, K., Kono, S., Liu, W., Omote, Y., Hishikawa, N., Deguchi, K., et al. (2014) · Journal of Stroke and Cerebrovascular Diseases · doi:10.1016/j.jstrokecerebrovasdis.2014.05.033 · Cited by 6
Lin, Y., Tsay, H.-J., Liao, Y., Wu, M.-F., Wang, C., & Shiao, Y. (2012) · Evidence-based Complementary and Alternative Medicine · doi:10.1155/2012/795843 · Cited by 6
Wang, J., Kong, X., Cong, L., Xu, Z., Du, J., Cong, X., Sun, H., Xu, Y., & Zhao, Q. (2018) · Journal of Integrative Neuroscience · doi:10.31083/j.jin.2018.04.0408 · Cited by 6
Islam, T., Gharibyan, A. L., Lee, C. C., & Olofsson, A. (2019) · BMC Biotechnology · doi:10.1186/s12896-019-0589-4 · Cited by 6
Self-citationRahimi-Balaei, M., Jiao, X., Dalvand, A., Shabanipour, S., Chung, S., Amiri, S., Kong, J., & Marzban, H. (2020) · Molecular Biology Reports · doi:10.1007/s11033-020-05614-0 · Cited by 6
Wu, D., Hu, Y., Song, M., & Li, G. (2021) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2021.634948 · Cited by 7
Andromidas, F., MacKinnon, B., Myers, A. J., Shaffer, M. M., Brahimi, A., Atashpanjeh, S., Vazquez, T. L., Le, T., Jellison, E. R., Staurovsky, S., et al. (2024) · Molecular and Cellular Neuroscience · doi:10.1016/j.mcn.2024.103975 · Cited by 4
An overview in interactions and biosensors of multiple biomarkers of Alzheimer’s disease
Chen, X., Wei, Y., Wang, X., Liu, X., & Wang, X. (2025) · Chemical Engineering Journal · doi:10.1016/j.cej.2025.161121 · Cited by 5
Structural changes to the basal forebrain cholinergic system in the continuum of Alzheimer disease
Taza, M., Schmitz, T. W., & Spreng, R. N. (2025) · Handbook of clinical neurology · doi:10.1016/b978-0-443-19088-9.00013-5 · Cited by 7
Liu, X., Zeng, Q., Luo, X., Li, K., Hong, H., Wang, S., Guan, X., Wu, J., Zhang, R., Zhang, T., et al. (2021) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2021.591347 · Cited by 5
Genome-Wide Selection Signal Analysis of Australian Boer Goat by Insertion/Deletion Variants
Yuan, Y., Yang, B., He, Y., Zhang, W., & E, G. (2022) · Russian Journal of Genetics · doi:10.1134/s1022795422120158 · Cited by 5
Patil, S. P., & Kuehn, B. R. (2024) · Pharmaceuticals · doi:10.3390/ph17040491 · Cited by 6
Pharmacological Activation of LXRs Decreases Amyloid-β Levels in Niemann-Pick Type C Model Cells
Štefulj, J., Perić, M., Malnar, M., Košiček, M., Schweinzer, C., Živković, J., Scholler, M., Panzenboeck, U., & Hecimovic, S. K. (2013) · Current Pharmaceutical Biotechnology · doi:10.2174/138920101131400224 · Cited by 5
Mai, Y., Cao, Z., Xu, J., Yu, Q., Yang, S., Tang, J., Zhao, L., Fang, W., Luo, Y., Lei, M., et al. (2022) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2022.859492 · Cited by 5
Zhou, S., & Sun, X. (2012) · PubMed · Cited by 5
Suenaga, M., Furuta, A., Wakabayashi, K., Saibara, T., & Matsunaga, Y. (2015) · Biochimica et Biophysica Acta (BBA) - Proteins and Proteomics · doi:10.1016/j.bbapap.2015.04.028 · Cited by 4
Bamel, K., Panwar, A., Kumar, M., Kumar, S., Sharma, V., & Sharma, A. K. (2025) · Brain Disorders · doi:10.1016/j.dscb.2025.100232 · Cited by 5
Metadata
- Authors
- Jiang, Q., Lee, C. Y. D., Mandrekar, S., Wilkinson, B., Cramer, P., Zelcer, N., Mann, K., Lamb, B., Willson, T. M., Collins, J. L., Richardson, J. C., Smith, J. D., Comery, T. A., Riddell, D., Holtzman, D. M., Tontonoz, P., & Landreth, G. E.
- Affiliations
- Case Western Reserve University (US)
- Howard Hughes Medical Institute (US)
- Cleveland Clinic (US)
- GlaxoSmithKline (United Kingdom) (GB)
- Wyeth (US)
- Washington University in St. Louis (US)
- Corresponding author
- Landreth, Gary E.
- ORCID
- Venue
- Neuron
- Publisher
- Elsevier BV
- Published
- 2008-06
- Volume
- 58
- Issue
- 5
- Pages
- 681-693
- ISSN
- 0896-6273 (ISSN-L)
- PMC
- PMC2493297
- OpenAlex
- W1994554610
- Cited by
- 876
- References
- 74
- Citations by year
- 2026: 15 · 2025: 34 · 2024: 33 · 2023: 37 · 2022: 35 · 2021: 42 · 2020: 42 · 2019: 47 · 2018: 46 · 2017: 50 · 2016: 57 · 2015: 60 · 2014: 70 · 2013: 70 · 2012: 56
- FWCI
- 41.19
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- Locations
- Neuron (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Data Archiving and Networked Services (DANS) (submittedVersion)
- Pure Amsterdam UMC (submittedVersion)
- Funders
- Howard Hughes Medical Institute
- National Institute on Aging (R01AG013956, R01AG020202, AG020202, R01AG030482, F32AG24031, F32AG024031, R37AG013956, AG13956)
- National Heart, Lung, and Blood Institute (HL3 0568, P01HL030568, R01HL066082, R01HL066088, HL66088)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Keywords
- apolipoprotein E, amyloid-beta, neprilysin, insulin-degrading enzyme, microglia, APOE isoforms, lipid modification, liver X receptor, GW3965, Tg2576 mice, Alzheimer's disease, memory impairment
- MeSH terms
- Liver X Receptors, Aging, Alzheimer Disease, Animals, Animals, Newborn, Apolipoproteins E, Behavior, Animal, Benzoates, Benzylamines, Brain, Cells, Cultured, Disease Models, Animal, DNA-Binding Proteins, Dose-Response Relationship, Drug, Enzyme-Linked Immunosorbent Assay, Memory, Mice, Inbred C57BL, Mice, Transgenic, Peptide Fragments, Time Factors, Amyloid beta-Peptides, Microglia, Receptors, Cytoplasmic and Nuclear, ATP-Binding Cassette Transporters, Mice, Orphan Nuclear Receptors, Plaque, Amyloid, ATP Binding Cassette Transporter 1
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
